Our look is new. Our purpose is the same. Learn more about our brand evolution.
How projects we have funded will help us get more and better treatments to our community by June Kinoshita, FSHD Society Many of you have heard us describe the FSHD […]
Steady improvement seen in data from open-label extension study Losmapimod, a drug that is currently in a Phase 3 clinical trial for FSH muscular dystrophy, continues to slow or stop […]
Updated 12-12-24 to reflect the chance in name from Epic Bio to Epicrispr Biotechnologies. Leading-edge CRISPR biotech chooses FSHD as its first disease target Epicrispr Biotechnologies, based in the San […]
